204 related articles for article (PubMed ID: 21215876)
1. Cabazitaxel for castration-resistant prostate cancer.
Shigeta K; Miura Y; Naito Y; Takano T
Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
[No Abstract] [Full Text] [Related]
2. Cabazitaxel for castration-resistant prostate cancer.
Froehner M; Wirth MP
Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
[No Abstract] [Full Text] [Related]
3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
5. Cabazitaxel in prostate cancer: stretching a string.
Dorff TB; Quinn DI
Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
[No Abstract] [Full Text] [Related]
6. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe A
Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
[No Abstract] [Full Text] [Related]
7. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
8. The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
[No Abstract] [Full Text] [Related]
9. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
Pouessel D; Oudard S; Gravis G; Priou F; Shen L; Culine S
Bull Cancer; 2012; 99(7-8):731-41. PubMed ID: 22743148
[TBL] [Abstract][Full Text] [Related]
10. Metastatic prostate cancer in 2015: The new and the old that is new again.
Graff JN; Beer TM
Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
[No Abstract] [Full Text] [Related]
11. Prolonging survival in prostate cancer: chemotherapy will have an important role.
Parker C; Emberton M
BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
[No Abstract] [Full Text] [Related]
12. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
13. STAMPEDE trial and patients with non-metastatic prostate cancer.
Gandaglia G; Fossati N; Suardi N; Montorsi F; Briganti A
Lancet; 2016 Jul; 388(10041):234-5. PubMed ID: 27479564
[No Abstract] [Full Text] [Related]
14. Defining new standards of care for men with prostate cancer.
Scher HI
Lancet; 2016 Mar; 387(10024):1135-7. PubMed ID: 27025318
[No Abstract] [Full Text] [Related]
15. Prostate cancer: Changing standard of care in hormone-sensitive disease.
Thoma C
Nat Rev Urol; 2016 Feb; 13(2):61. PubMed ID: 26787390
[No Abstract] [Full Text] [Related]
16. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
19. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
Printz C
Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
[No Abstract] [Full Text] [Related]
20. [Current strategies of intermittent hormone therapy in prostate cancer].
Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]